Welcome to our dedicated page for Bionano Genomics news (Ticker: BNGO), a resource for investors and traders seeking the latest updates and insights on Bionano Genomics stock.
Bionano Genomics, Inc. (Nasdaq: BNGO) is a pioneering company in the life sciences instrumentation sector, dedicated to advancing genome biology understanding through innovative solutions. The company is renowned for its development and marketing of the Saphyr™ system, an ultra-sensitive platform designed for structural variation detection. This system enables researchers and clinicians to accelerate diagnostics and therapeutic target discovery, streamlining studies on chromosomal changes.
Bionano's core mission is to transform genomic analysis through optical genome mapping (OGM) solutions, diagnostic services, and software. Their flagship product, Saphyr™, offers unmatched capabilities in structural variation discovery and the ability to construct comprehensive genome assemblies. This technology is crucial for applications in cancer research, human disease studies, agricultural bioengineering, and genome discovery.
Recent achievements include the detection of unique structural variations and gene fusions in blood cancer samples, underscoring OGM's potential as a complement to traditional sequencing methods. Bionano's OGM technology has shown superior sensitivity and resolution in various studies, highlighting its utility in pediatric leukemia and other cancers.
The company operates globally with significant revenue from the Americas, and it generates product revenue from the sales of OGM and Ionic Purification systems and consumables. Bionano also offers diagnostic testing for neurodevelopmental disabilities through its Lineagen, Inc. d/b/a Bionano Laboratories business and industry-leading genome analysis software that integrates next-generation sequencing and microarray data.
Partnerships with AI-driven companies like Diagens further enhance Bionano's offerings, aiming to improve reproductive health and other clinical applications. Additionally, Bionano continuously upgrades its VIA software and Bionano Solve pipeline to provide researchers with precise and sensitive genomic research tools.
For more information, visit Bionano Genomics and its associated websites, www.bionanolaboratories.com and www.purigenbio.com.
Bionano Genomics (BNGO) reported its financial results for Q4 2020, highlighting a revenue increase of 43% to $4 million compared to Q4 2019, primarily due to growth in service revenue from Lineagen. However, total revenue for 2020 decreased by $1.6 million to $8.5 million, impacted by COVID-19. The company raised approximately $335 million in early 2021, strengthening its balance sheet. They aim to enhance the adoption of their Saphyr® system in clinical testing and have ambitious milestones planned for 2021, including the expansion of clinical assays.
Bionano Genomics has announced its participation in two virtual investor conferences. Management will present at the Oppenheimer 31st Annual Healthcare Conference on March 17, 2021, at 11:20 AM ET. Additionally, presentations will be available at the Maxim Group's Emerging Growth Conference from March 17-19, 2021. Webcasts will be accessible on Bionano's website for 30 days post-event.
Bionano Genomics (NASDAQ: BNGO) presented virtually at the H.C. Wainwright Global Life Sciences Conference held on March 9-10, 2021. CEO Dr. Erik Holmlin's presentation is available on-demand on the conference portal and Bionano's investor page for 30 days post-event. Bionano specializes in genome analysis with its Saphyr system, designed for structural variation detection. This platform enables researchers to enhance diagnostics and therapeutic targets. Lineagen, a Bionano subsidiary, has provided over 65,000 genetic tests for neurodevelopmental disorders, including ASD.
Bionano Genomics (BNGO) will host a conference call and webcast on March 23, 2021, at 4:30 p.m. Eastern Time to discuss its fourth quarter and year-end financial results for 2020. The company will also highlight recent corporate advancements. Participants can join the call by dialing the provided toll-free or international numbers. Bionano provides genome analysis tools via its Saphyr system, aimed at enhancing genetic research and diagnostics.
Bionano Genomics (BNGO) announced that Praxis Genomics received DEX Z-codes from Palmetto MolDX for its complete menu of laboratory developed tests (LDTs) based on the Saphyr system. These codes enhance clarity for payers regarding molecular diagnostics tests and could accelerate claim payments. Praxis is the first CAP-accredited lab in the U.S. to offer LDTs based on whole genome analysis with Saphyr, potentially leading to Medicare and private insurance reimbursement for optical genome mapping (OGM) tests. Bionano aims to improve the Saphyr system's throughput to 17,000 samples annually by mid-2023.
Bionano Genomics (Nasdaq: BNGO) announced that its CEO, Erik Holmlin, will present virtually at the Cowen 41st Annual Health Care Conference on March 4, 2021, at 2:10 PM EST. The presentation will be accessible via a live webcast on Bionano's Investors section and will be archived for 30 days post-event. Bionano specializes in genome analysis tools, particularly through its Saphyr system, which aids in structural variation detection for genetic research.
Bionano Genomics (BNGO) announced its participation in the 2021 Advances in Genome Biology and Technology (AGBT) meeting, showcasing its Saphyr System for optical genome mapping. The virtual conference, held from March 1-3, will feature presentations from leading institutions, including Boston Children’s Hospital and Harvard Medical School, focusing on psychiatric disorders and cancer.
Key activities include a plenary talk on pediatric psychiatric disorders and various poster presentations. Bionano's CEO and CMO will also participate in a live interview during the conference.
Bionano Genomics announced a significant contribution of its optical genome mapping (OGM) technology to a study published in Science, unveiling thousands of large structural variant calls not captured by traditional methods. The study showcased 64 haplotype-resolved genomes, enhancing understanding of human genetic diversity. OGM identified 5,590 large structural variants, crucial for understanding genetic disorders. This advancement underscores OGM's role in genome analysis, urging researchers to integrate structural data for deeper insights into genetic variation.
Bionano Genomics announced the publication of a study from its Lineagen team that introduces a groundbreaking scoring algorithm called NeuroSCORE. This model evaluates nearly all protein-coding genes for their potential to cause central nervous system (CNS) disorders. By integrating this with the Saphyr platform, the company enhances its diagnostic capabilities. NeuroSCORE combines data from multiple databases, allowing for better identification of variants of unknown significance (VUS) and potentially discovering novel genes linked to conditions like autism spectrum disorder.
Bionano Genomics (Nasdaq: BNGO) will present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2021, at 1:30 PM PST. CEO Erik Holmlin will participate in a fireside chat. A live webcast can be accessed on Bionano’s Investors website and will be archived for 30 days. Bionano specializes in genome analysis and diagnostic testing through its Saphyr system and Lineagen business, focusing on autism spectrum disorder and other neurodevelopmental disabilities.
FAQ
What is the current stock price of Bionano Genomics (BNGO)?
What is the market cap of Bionano Genomics (BNGO)?
What does Bionano Genomics, Inc. specialize in?
What is the Saphyr™ system?
What are the applications of Bionano's OGM technology?
What recent achievements has Bionano reported?
Where does Bionano operate?
What additional services does Bionano offer?
Who are Bionano's key partners?
What is the purpose of Bionano's VIA software?
Are Bionano's products for research or clinical use?
How can I learn more about Bionano Genomics?
